Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Post by donmayneon Feb 16, 2022 9:45am
271 Views
Post# 34433261

Options, RSU and Phantom Shares

Options, RSU and Phantom SharesAfter the spinoff at the end of 2017, one of the first activities in 2018 for VMD was to award stock compensation packages to senior management.  Each year, in January they make the awards and have committed to a maximum of 20% of the authorized shares over a ten year period.  The awards to Directors is done in the late summer and is at a much smaller scale.  Here are the aggregate awards since the spinoff.

Options granted to management insiders
Date of Grant Options granted Exercise Price Expiry date 1/3 Vesting
04-Jan-18      563,737 2.27 Cdn 04-Jan-28 Yrs 1, 2 & 3
17-Jan-19      786,452 5.49 Cdn 17-Jan-29 Yrs 1, 2 & 3
17-Jan-20      640,835 7.44 Cdn 17-Jan-30 Yrs 1, 2 & 3
21-Jan-21      524,711 10.63 Cdn 21-Jan-31 Yrs 1, 2 & 3
18-Jan-22      371,102 5.21 US 18-Jan-32 Yrs 1, 2 & 3
18-Jan-22      252,345 RSUs 18-Jan-25 Yrs 1, 2 & 3
18-Jan-22      123,692 Phantom Sh 18-Jan-25 Yrs 1, 2 & 3

A year ago on Feb 16, 2021 the closing price was $13.14 Cdn.  The total value of the above awards would have been roughly $17.1 million Cdn.  Note: This excludes the 2022 awards.

The closing price of Feb 15, 2022 was $5.29 Cdn.  At this price the total value of the above awards would be roughly $3.7 million Cdn. Note: This includes the 2022 awards.

If the share price were to recover to the price of one year ago, then the total value of the above awards would be $24.5 million Cdn.  That is a significant incentive.

It is noteworthy that the expiry dates for the 2022 RSU and Phantom share awards are much shorter than the option expiry dates.

The share price decline has seriously eroded the value of the above awards but there is now a huge incentive for management to show that they can address the uncertainty of the CMS repayment, grow patient numbers at a 40% rate in their core business and engage in promotion of the company to new investors to expand the PE multiple.   

It is helpful for shareholders to realize that management could have exercised these awards when the share price was in the low teens.  They did exercise some options that they carried forward from pre-merger days just as those options were expiring.  Coincidently that was done just prior to the release of the OIG report.  So they did manage to extract some value before the negative impact caused by the OIG report.  

In the last year, they lost their two largest passive investors according to 13G filings.  CI Investments and Claret Asset Management sold 4.7 million shares.  The selling of their holdings were instrumental in the recent steady persistent decline was because those shares had to be picked up by the retail market during a time when the company's performance was lackluster due to the pandemic.  The trade volume on Feb 15, 2022 suggests a capitulation on that day so perhaps we will start seeing a rising price. A private Alabama based investment fund, Forager Capital, purchased 1.3 million shares which suggests that local networking with investors might be worthwhile. Institutional buyers hesitate when they see persistent offloading by big investors.  They may decide to pick up shares if there is an upward momentum.

I am hoping for some meaningful post-pandemic guidance in the annual filing and CC.  We should soon see an announcement as to the date for this release.  Senior management is accountable to the shareholders and they could benefit with a refresh of their approach to reporting.  


<< Previous
Bullboard Posts
Next >>